Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, chronic pain, hemophilia, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop NKTR-214, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.
| Website: | www.nektar.com |
| Email: | Investors@nektar.com |
| Main Phone: | +1 415 482-5300 |
| Address: | 455 Mission Bay Boulevard South |
| State: | CA |
| City / Town: | San Francisco |
| Country: | USA |
| Postal Code: | 94158 |
| Exchange: | NGS |
| CEO: | Howard W. Robin |
| Employees: | 509 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 36.66 | Change $ -0.33 | Change % -0.89 | Tick N/A |
| Bid 36.68 | Bid Size 200.00 | Ask 37.75 | Ask Size 1,000.00 |
| Open 36.91 | High 37.53 | Low 35.57 | Prev Close 36.99 |
| Last Trade | Volume 1.8 mi | 52 Wk Hi 111.36 | 52 Wk Low 33.50 |
| Market Cap 6.3 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 173,085,231.00 | EPS (TTM) 3.96 | PE Ratio 9.30 | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 54 | 154 |
| Number of Buys | 27 | 78 |
| Number of Sells | 27 | 76 |
| Net Activity | 1280 | 285373 |
| Last 10 Buys | Shares |
|---|---|
| Roy A. Whitfield | 1,000 |
| Roy A. Whitfield | 1,000 |
| Roy A. Whitfield | 1,000 |
| Roy A. Whitfield | 1,000 |
| R. Scott Greer | 1,000 |
| Dennis L. Winger | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| R. Scott Greer | 1,000 |
| Robert B. Chess | 1,000 |
| R. Scott Greer | 1,000 |
| John Nicholson | 1,000 |
| Jillian B. Thomsen | 1,000 |
| Howard W. Robin | 1,000 |
| Stephen K. Doberstein | 1,000 |
| Maninder Hora | 1,000 |
| Gil M. Labrucherie | 1,000 |
| Robert B. Chess | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 125 | 125 | 125 | 125 |
| Low Target Price Estimate | 63 | 63 | 63 | 54 |
| Mean Target Price Estimate | 98.22 | 102.67 | 102.67 | 93.44 |
| Standard Deviation | 19.08 | 19.72 | 19.72 | 24.14 |
| Date of Most Recent Estimate | 06/04/18 | 05/16/18 | 05/16/18 | 06/11/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-07 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-06 |
| 8-K | Report of unscheduled material events or corporate changes. | 14 | 2018-06-04 |
| CT ORDER | 1 | 2018-05-22 | |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 8 | 9 | 8 | 6 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 2 | 1 | 1 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.4 | 1.2 | 1.22 | 1.29 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
